BioNTech SE Sponsored ADR $BNTX Shares Acquired by Invesco Ltd.

Key Points

• Invesco Ltd. increased its stake in BioNTech SE by 643.7% during the first quarter, owning approximately $58.75 million worth of shares at the end of the most recent reporting period.
• Despite a negative EPS of ($1.60) reported in its latest earnings, BioNTech's revenue increased by 102.6% year-over-year, totaling $306.46 million compared to analyst estimates.
• Research analysts have mixed outlooks on BioNTech, with target prices ranging from $116 to $150, indicating a consensus rating of "Moderate Buy."

Invesco Ltd. grew its stake in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 643.7% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 645,142 shares of the company's stock after acquiring an additional 558,389 shares during the quarter. Invesco Ltd. owned about 0.27% of BioNTech worth $58,747,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Probity Advisors Inc. grew its holdings in shares of BioNTech by 8.5% during the 4th quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after purchasing an additional 154 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of BioNTech by 9.1% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,494 shares of the company's stock worth $227,000 after purchasing an additional 209 shares during the period. SBI Securities Co. Ltd. grew its holdings in shares of BioNTech by 7.1% during the 1st quarter. SBI Securities Co. Ltd. now owns 3,673 shares of the company's stock worth $334,000 after purchasing an additional 244 shares during the period. Banque Cantonale Vaudoise purchased a new stake in shares of BioNTech during the 1st quarter worth about $36,000. Finally, GF Fund Management CO. LTD. grew its holdings in shares of BioNTech by 22.0% during the 1st quarter. GF Fund Management CO. LTD. now owns 2,514 shares of the company's stock worth $229,000 after purchasing an additional 453 shares during the period. Institutional investors and hedge funds own 15.52% of the company's stock.

BioNTech Stock Down 0.5%

Shares of BNTX traded down $0.53 during trading on Thursday, reaching $110.77. The company's stock had a trading volume of 697,025 shares, compared to its average volume of 691,933. The company has a fifty day moving average of $109.81 and a two-hundred day moving average of $105.64. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $131.49. The company has a market cap of $26.63 billion, a price-to-earnings ratio of -69.23 and a beta of 1.23. The company has a quick ratio of 8.48, a current ratio of 8.61 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($1.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. During the same period in the previous year, the company earned ($3.36) earnings per share. The business's revenue for the quarter was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of research reports. Leerink Partners set a $112.00 target price on BioNTech in a report on Monday, June 2nd. Bank of America boosted their target price on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a report on Tuesday, August 5th. The Goldman Sachs Group initiated coverage on BioNTech in a report on Thursday, May 29th. They issued a "neutral" rating and a $110.00 price target for the company. JPMorgan Chase & Co. decreased their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating for the company in a report on Thursday, May 22nd. Finally, HC Wainwright decreased their price target on BioNTech from $138.00 to $136.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Thirteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $135.80.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.